Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 positive |
Therapy | Alofanib |
Indication/Tumor Type | ovarian cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 positive | ovarian cancer | predicted - sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) inhibited growth in an ovarian cancer cell line expressing FGFR2 in culture (PMID: 27136102). | 27136102 |
PubMed Id | Reference Title | Details |
---|---|---|
(27136102) | Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. | Full reference... |